Key Stats
- Founded: January 8, 1988 in Tarrytown, New York
- 2024 Revenue: $14.20 billion (8.27% year-over-year growth)
- 2024 Employees: 15,100+ colleagues worldwide
- Market Cap: Approximately $80 billion (February 2026)
- FDA-Approved Medicines: 14 (including 4 blockbuster drugs)
Regeneron Pharmaceuticals ranks among the largest biotechnology companies in the world. The company discovers, develops, manufactures, and commercializes medicines for serious diseases. Headquartered in Tarrytown, New York, Regeneron focuses on treatments for eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, and rare genetic disorders.
The company operates through proprietary technologies including VelociSuite, which produces optimized fully human antibodies and bispecific antibodies. Regeneron trades on NASDAQ under the ticker symbol REGN. Its approved products include EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for certain cancers, and Praluent for cholesterol management.
Regeneron Pharmaceuticals History
Regeneron Pharmaceuticals Co-founders
Regeneron Pharmaceuticals Revenue
Regeneron generated $14.20 billion in total revenue for fiscal year 2024. This represented an 8.27% increase from the prior year’s $13.12 billion.
Revenue peaked at $16.1 billion in 2021 due to COVID-19 antibody sales. The company’s four blockbuster medicines, EYLEA, Dupixent, Libtayo, and Praluent, drive the majority of current revenue growth.
Regeneron Pharmaceuticals Acquisitions
Regeneron has pursued targeted acquisitions to expand its pipeline and therapeutic capabilities. Unlike some pharmaceutical companies that grow through large-scale mergers, Regeneron has focused on smaller strategic deals that complement its internal research programs.
In April 2022, Regeneron acquired Checkmate Pharmaceuticals for approximately $250 million. The deal added vidutolimod, a TLR9 agonist with clinical activity in PD-1 refractory melanoma, to the company’s immuno-oncology portfolio. Checkmate’s virus-like particle delivery platform expanded Regeneron’s combination therapy options for difficult-to-treat cancers.
Regeneron completed the acquisition of Decibel Therapeutics in October 2023 for $109 million plus contingent value rights. Decibel’s lead program, DB-OTO, is a gene therapy designed to restore hearing in people with otoferlin-related deafness. The company reported encouraging clinical results in 2025, with plans to seek FDA approval.
In January 2024, Regeneron acquired 2seventy bio’s cell therapy pipeline for $5 million upfront plus milestone payments and royalties. The deal included clinical-stage CAR T programs and discovery platforms. Regeneron formed a new division called Regeneron Cell Medicines to advance these programs.
The company acquired Oxular in January 2025, adding ophthalmic drug delivery technology to its eye disease portfolio. Regeneron also bid $256 million for 23andMe during the genetic testing company’s bankruptcy proceedings in 2025, gaining access to its biobank and consumer genomics platform.
Regeneron Pharmaceuticals Market Cap
Regeneron Pharmaceuticals maintains a market capitalization of approximately $80 billion as of February 2026. The company reached its all-time high stock price of $1,195.13 in August 2024.
Market cap has grown substantially since the company’s IPO in 1991 when it raised $91 million. By 2019, Regeneron ranked as the 7th best-performing stock of the 2010s with a total return of 1,457%.
Regeneron Pharmaceuticals Competitors
Regeneron competes with major pharmaceutical and biotechnology companies across multiple therapeutic areas. Competition intensifies in ophthalmology, immunology, and oncology segments where several companies offer similar treatments.
| Company | Headquarters | Primary Therapeutic Areas |
|---|---|---|
| Amgen | Thousand Oaks, California | Oncology, Cardiovascular, Inflammation |
| Gilead Sciences | Foster City, California | Antivirals, Oncology, Inflammation |
| Biogen | Cambridge, Massachusetts | Neuroscience, Rare Diseases |
| Roche/Genentech | Basel, Switzerland | Oncology, Ophthalmology, Immunology |
| Novartis | Basel, Switzerland | Oncology, Cardiovascular, Ophthalmology |
| AbbVie | North Chicago, Illinois | Immunology, Oncology, Aesthetics |
| Bristol Myers Squibb | New York, New York | Oncology, Immunology, Cardiovascular |
| Vertex Pharmaceuticals | Boston, Massachusetts | Cystic Fibrosis, Rare Diseases, Pain |
| Moderna | Cambridge, Massachusetts | Vaccines, Oncology, Rare Diseases |
| Alexion (AstraZeneca) | Boston, Massachusetts | Rare Diseases, Hematology |
FAQs
When was Regeneron Pharmaceuticals founded?
Regeneron Pharmaceuticals was founded on January 8, 1988 by Leonard S. Schleifer in Tarrytown, New York. George D. Yancopoulos joined the following year as Chief Scientific Officer.
What are Regeneron Pharmaceuticals most successful drugs?
Regeneron’s most successful drugs include EYLEA for eye diseases, Dupixent for allergic conditions, Libtayo for cancer, and Praluent for high cholesterol. All four generate over $1 billion annually.
Who owns Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is publicly traded on NASDAQ under the symbol REGN. Co-founders Leonard Schleifer and George Yancopoulos hold significant ownership stakes. Sanofi reduced its stake in 2020.
What is Regeneron Pharmaceuticals revenue?
Regeneron generated $14.20 billion in total revenue for fiscal year 2024. This represented an 8.27% increase from the previous year’s revenue of $13.12 billion.
Where is Regeneron Pharmaceuticals headquarters located?
Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, located in Westchester County. The company operates research and manufacturing facilities in New York and is expanding in North Carolina.